Detail akcie Uniqure online

Business Summary: Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Uniqure NV revenues increased from $7.7M to $19.6M. Net loss decreased 16% to $121.9M. Revenues reflect Collaboration revenues increase from $707K to $10.4M, License revenues increase from $793K to $3.1M. Lower net loss reflects Research and development expenses decrease of 34% to $39.7M (expense), Selling, General & Administrative exp. decrease of 42% to $11M (expense).